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Structured Abstract 
Aims: To investigate the validity and reliability of the 6-item DAWN2 Impact of 
Diabetes Profile (DIDP), and the modified 7-item DIDP, which includes assessment 
of dietary freedom. 
Methods: The online, cross-sectional, Australian MILES-2 survey included the DIDP 
and other validated measures, to examine convergent, discriminant and known-
groups validity. The DIDP was completed by 2,207 adults with diabetes (Type 1: 
n=1,012; Type 2 insulin: n=504; non-insulin: n=691). Data were subjected to 
exploratory factor analysis, internal consistency reliability and univariate statistics, 
conducted separately by diabetes type/treatment. 
Results: The DIDP was highly acceptable: 99% completion rate. One-factor 
solutions were supported for the 6-item and 7-item DIDP scales, in all diabetes 
type/treatment groups (variance explained range: 6-item: 59%-67%, 7-item: 55%-
62%), with satisfactory internal consistency (α=0.85-0.90). Known-groups validity 
was demonstrated, by diabetes type and complications presence/absence, as was 
satisfactory convergent and discriminant validity. 
Conclusions: The DIDP meets the need for a brief, contemporary, valid and reliable 
measure of the perceived impact of diabetes on quality of life, suitable for adults with 
Type 1 or Type 2 diabetes mellitus. The 6-item and 7-item scales have psychometric 
equivalence. Use of the seventh item can be informed by research questions. 
Abstract word count: 192 
Key words: Patient-reported outcomes, quality of life, psychosocial issues 
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1. Introduction  
As living with diabetes permeates every aspect of life and is relentless across the 
lifespan, it is widely acknowledged that diabetes can impair quality of life [1, 2]. 
Furthermore, quality of life has long been recognised as an important clinical 
outcome, in addition to biomedical risk markers and outcomes, and indicator of 
whether or not a medical treatment is beneficial [3]. 
Thirty years ago, there was considerable academic and clinical interest in 
recognising the impact of diabetes on quality of life, resulting in the development of 
three measures of diabetes-specific quality of life [4-6]. While interest has remained, 
the complexity of assessing and interpreting quality of life measures has been 
recognised [7, 8]. Meanwhile, attention has turned to the assessment of other 
diabetes-specific psychological constructs that may have greater clinical utility, e.g. 
diabetes distress [9] and fear of hypoglycaemia [10]. While such constructs have 
been referred to as ‘markers’ of quality of life [11], they assess the person’s feelings 
about managing various aspects of their diabetes rather than assessing how 
diabetes affects various aspects of their life. Currently, the measures designed to 
assess the impact of diabetes on quality of life are typically lengthy (e.g. three widely 
used measures: >40 items [4-6]) and may be complex for both the respondent and 
the clinician/researcher [7,8]. Thus, there is currently an unmet need for a simple, 
brief measure focused on the impact of diabetes on key dimensions of life of 
importance to people with diabetes.  
The DAWN2 Impact of Diabetes Profile (DIDP) was designed for inclusion in the 
multi-national DAWN2 study to provide a brief assessment of the perceived impact of 
diabetes on six key dimensions of life (see Table 1) [12, 13]. Spanning 17 countries, 
DAWN2 surveyed 9,040 adults with Type 1 (T1DM) and Type 2 diabetes mellitus 
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(T2DM). DAWN2 findings, including DIDP descriptive statistics and correlates, have 
been published elsewhere [13, 14]. However, the psychometric properties of the 
DIDP have not yet been examined separately by diabetes type/treatment. The aim of 
the current study was to investigate the psychometric properties of the DIDP among 
adults with T1DM and T2DM (insulin and non-insulin treated) in a large Australian 
sample, using data from the second Diabetes MILES – Australia Study (MILES-2) 
[15]. 
2. Participants, Material and Methods 
2.1. Study design 
MILES-2 was a large-scale national online survey of Australians with diabetes, 
completed in 2015. A detailed description of MILES-2, including methods and 
response rates, has been published elsewhere [15]. The study was conducted 
according to the CHEcklist for Reporting Results of Internet E-Surveys (CHERRIES) 
[16]. Ethics approval: Deakin University Human Ethics Committee (2011-046). 
2.2. Participants, recruitment and procedure 
Eligible participants were aged 18-75 years, with a self-reported diagnosis of T1DM 
or T2DM, English speaking, and currently residing in Australia. Study invitations 
were posted to a computer-generated random sample of 20,000 consenting National 
Diabetes Services Scheme (NDSS) registrants (stratified according Australian 
state/territory, and by diabetes type/treatment). The NDSS provides subsidised 
products, information and support services to >1.2 million Australians with diagnosed 
diabetes [17]. Invitations were also distributed to consenting participants of the first 
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Diabetes MILES – Australia (2011) survey (N=2,065), and promoted online (i.e. 
website, e-newsletters, and social media sites). 
Participants were directed to a website including the study plain language statement 
and survey (securely hosted by Qualtrics, Copyright © 2015, Provo, UT). After 
indicating consent and being screened for eligibility, participants proceeded to the 
survey proper. The final eligible MILES-2 sample included 2,342 participants [15]. 
Survey responses were saved automatically, whereby the participant data are 
available for the portion of the survey they completed prior to exiting the survey. A 
total of 130 (5.6%) participants exited the survey prior to commencing the DIDP and 
are excluded from analysis.  
2.3. Measures 
Full details of the measures included in MILES-2 are published elsewhere [15]. 
2.3.1. DAWN2 Impact of Diabetes Profile  
The DAWN2 survey design, including development of the DIDP, was overseen by 
the Global DAWN2 Survey Working Group and is detailed elsewhere [12]. Survey 
refinement involved input from representatives of all countries participating in 
DAWN2, including study partners and multiple collaborating organisations, scientific 
experts, and participant groups (e.g. people with diabetes). 
Several criteria guided the design of the DIDP: it should be very brief; include main 
global dimensions of life as identified from past multi-national qualitative research 
[12, 18]; be easy to read and understand (suitable for people with low literacy); 
enable respondents to express both negative and positive impacts of diabetes; 
enable comparison across diverse populations (within and across diabetes types, 
treatments); be suitable for development of comparable versions for completion by 
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caregivers and for the development of cross-culturally equivalent versions in multiple 
languages. Development of the English version of the DIDP involved user-testing 
with seven people with diabetes to assess and improve face validity, acceptability 
and readability [12]. Following approval of the English version, national experts 
reviewed and approved 22 local language versions applied in each of the 17 
countries. Where feasible, the wording of each version was reviewed by people with 
diabetes in relevant countries. DIDP versions were also developed for completion by 
family members [12, 13, 19]. The current study focuses solely on the English DIDP 
version developed for completion by adults with diabetes.  
The final DIDP scale, as used in DAWN2 [12], asks respondents to rate how 
diabetes currently impacts upon each of six dimensions of their life (See 
Supplementary file 2). Each item is rated on a 7-point scale (1=very positive impact, 
4=no impact, 7=very negative impact). A ‘not applicable’ (N/A) response option is 
also available for each item. At the point of using the DIDP in the Australian MILES-2 
study, a seventh dimension (dietary freedom) was added based upon the 
established highly negative impact of diabetes on dietary freedom and its importance 
for overall quality of life [20-22].  
Each DIDP item was developed to reflect a distinct dimension of life that can be 
interpreted and reported individually [12]. To reflect total impact of diabetes across 
all life dimensions, a DIDP composite scores can be calculated by summing 
responses for each item and dividing by the number of complete responses (i.e. not 
missing or N/A). In the current study both composite raw composite scores (1-7) and 
converted percentage (0-100%) scale scores are reported. Lower scores indicate 
greater positive impact and higher scores indicate greater negative impact across 
global life dimensions.  
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2.3.2. Measures used for validation purposes  
Several measures (described below) were included in the current study to assess 
the convergent, divergent and known-groups validity of the DIDP scale scores 
(described in Statistical Analyses). It was hypothesised that DIDP composite scale 
scores would show a strong positive association with diabetes-specific distress, and 
moderate positive associations with depressive and anxiety symptoms (convergent 
validity); while weak correlations would be observed with general prospective and 
retrospective memory, diabetes duration and self-reported HbA1c (divergent validity). 
All patient-reported outcome measures used for validation purposes in this study 
exhibited acceptable internal consistency reliability (Cronbach’s α>0.85). Drawing on 
the existing literature [e.g. 5, 6, 14, 22, 32, 33], expected differences between known 
groups were examined by diabetes type/treatment, insulin modality, experience of 
severe hypoglycaemia, and presence of diabetes-related complications.   
2.3.2.1. Diabetes-specific distress 
Diabetes-specific distress was assessed using the 20-item Problem Areas In 
Diabetes Scale (PAID) scale [9]. Respondents indicate how much of a problem each 
statement is for them on a 5-point Likert scale (0=not a problem to 4=serious 
problem). Items are summed and converted to a percentage score (0-100), with 
higher scores indicating greater diabetes distress.  
2.3.2.2. Depression and anxiety symptoms 
General depressive and anxiety symptoms were measured with the Patient Health 
Questionnaire 8-item scale (PHQ-8) [23] and Generalised Anxiety Disorder 7-item 
scale (GAD-7) [24]. Respondents indicate how frequently they have experienced 
symptoms of depression or anxiety over the past two weeks on a four-point Likert 
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scale (0=not at all to 3=nearly every day). Higher scores indicate more 
depressive/anxiety symptoms. Responses are summed to produce a total score 
(range: PHQ-8=0-24, GAD-7=0-21).   
2.3.2.3. Prospective and retrospective memory  
Prospective and Retrospective Memory Questionnaire (PRMQ) assesses general 
prospective and retrospective memory [25]. Respondents indicate how frequently 
they experience 16 memory ‘slips’ on a 5-point Likert scale (1=never to 5=very 
often). Responses are summed to produce a total score (range: 16-80), with higher 
scores indicating more memory problems.  
2.3.2.4. Demographic and clinical characteristics 
Participants were asked to self-report demographic characteristics and clinical 
characteristics (see Table 1). 
2.4. Statistical analyses 
Unless noted otherwise, all statistical analyses were conducted separately for three 
groups: T1DM, non-insulin-treated and insulin-treated T2DM. Missing data was 
minimal (<5%) on measures used to assess validity. Pairwise deletion of missing 
values was used to minimise loss of data. Valid percentage is reported.  
High completion rates (≥90%) are taken as evidence of the acceptability of the DIDP. 
Descriptive statistics were used to identify response patterns, item floor/ceiling 
effects (i.e. >20% participants rating minimum/maximum possible response) [26].The 
Kolmogorov-Smirnov test of normality was applied to assess the distribution of the 
data. All data were distributed non-normally, necessitating the use of nonparametric 
statistics.  
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Barlett’s Test of Sphericity was assessed to check for correlation between items and 
the determinant was screened for multicollinearity. Two-tailed inter-item Spearman’s 
rho (rs) correlations were used to identify items with very high (rs>0.7) or very low 
(rs<0.3) inter-item correlations. A Kaiser-Meyer-Olkin statistic of >0.05 for all 
subgroups indicated sample size adequacy [27]. The structural validity of the 
questionnaire was assessed using principal axis factoring analysis. The Kaiser-
criterion (Eigenvalue ≥ 1), percentage variance explained by each factor, and factor 
loadings were inspected to assess whether the expected single-factor structure was 
supported. Factor loadings were considered meaningful if ≥0.5 [28]. Cronbach’s 
alpha and Guttman’s Lambda [29] were used to assess internal consistency 
reliability (i.e. how well the items in a scale measure the same underlying construct), 
with α≥0.7 considered satisfactory and α>0.95 indicating item redundancy.  
Correlations with measures used for validation purposes were calculated for scale 
scores and individual dimensions. Moderate (rs>±0.3) and strong (rs>±0.5) 
correlations were taken as evidence for convergent validity (i.e. whether two 
measures that should be related are actually related). Weak correlations (rs<±0.3) 
were taken as evidence of discriminant validity (i.e. whether two measures that 
should be unrelated actually measure dissimilar constructs) [30]. Known groups 
validity is a test of whether a measure can discriminate between two groups on the 
variable of interest. It was examined by comparing (Mann-Whitney test or Kruskal-
Wallis test) item and DIDP scale scores by: diabetes type/treatment (T1DM; T2DM 
insulin-treated type 2; T2DM non-insulin-treated); insulin administration 
(injections/pump, T1DM sample only); severe hypoglycaemia episode in past 6 
months (yes/no, insulin-treated samples only); diabetes-related complications 
(none/≥1).  
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Statistical analyses were conducted using IBM SPSS version 22 (Chicago, IL, USA). 
An alpha level of p<0.05 was taken to indicate significance. Data are reported as 
mean±SD, median (quartile 1, quartile 3) or n(%). 
3. Results 
3.1. Sample characteristics 
The DIDP was attempted (completion of ≥1 item) by 2,207 participants (T1DM: 
n=1,012, T2DM non-insulin-treated: n=691, T2DM insulin-treated: n=504). 
Participant demographic, clinical and psychosocial characteristics are shown in 
Table 1 (N=2207).  
---Table 1--- 
3.2. Acceptability, applicability and response patterns 
The DIDP was received by 2,212 participants and 99.4% completed all 7 DIDP 
items. Five participants skipped the entire scale, one skipped two items, and seven 
skipped a single item. Most participants perceived all DIDP items to be applicable 
(T1DM: 91%, n=917; insulin-treated T2DM: 85%, n=427; non-insulin-treated T2DM: 
84%, n=582). The item most commonly reported as N/A was ‘work/studies’ (10.5%, 
n=232) while all other items were reported as N/A by ≤3.5%. Response patterns by 
diabetes subgroup are available in Supplement 1. The full range of response options 
was used for every item. Where the aspect of life was deemed applicable, the 
distribution of responses was negatively skewed, with the majority of responses 
indicating no impact to a slight negative impact. No ceiling or floor effects were 
observed for any items. Descriptive statistics for each dimension are shown in Table 
1. 
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3.3. Scale structure 
Within the DIDP, medium-to-large inter-item relationships were observed (rs=0.30-
0.63) and multicollinearity was not a problem (determinant value >0.0001). Table 2 
displays scale structure and internal consistency reliability for the 6-item and 7-item 
scales, by diabetes type/treatment.  
---Table 2--- 
For the 6-item scale, a single-factor structure was observed, explaining between 59 
and 67% of total scale variance. Internal consistency was high across diabetes 
type/treatment groups (α=0.85-0.90). The additional item (‘dietary freedom’) loaded 
>0.5 for all groups, but a small decrease was observed in the total scale variance 
explained (difference: -2.8 to -5.6%), and marginally different reliability results were 
observed (α=0.86-0.88) across groups.  
To assess how many complete responses (i.e. not missing or N/A) per participant 
are required to retain strong internal consistency, Cronbach’s alpha was recalculated 
iteratively (after deleting the item with the strongest item-total correlation) until 
reliability was compromised (α<0.70). Across groups, ≤2 missing or N/A responses 
were tolerated on the 6-item scale, and ≤3 on the 7-item scale. DIDP composite 
scores (Table 1) are calculated using this approach. Mean scale scores trend 
towards a slight negative impact of diabetes across dimensions of life. 
3.4. Convergent, divergent, and known-groups validity  
Table 3 displays correlations between the DIDP dimensions, scale scores and 
various self-reported clinical and psychosocial measures. Hypothesised convergent 
validity was supported for the T1DM sample: strong correlations were observed with 
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diabetes-specific distress (PAID), and moderate correlations with generic anxiety 
(GAD-7) and depressive symptoms (PHQ-8), for the 6-item and 7-item DIDP scale 
scores. In the T2DM samples, regardless of treatment type, convergent validity 
hypotheses were not supported for the scale scores, with one exception. Moderate 
positive correlations were observed for both the 6-item and 7-item DIDP scale scores 
and depressive symptoms (PHQ-8) for participants with non-insulin treated T2DM.  
At the item level, diabetes-specific distress was at least moderately (rs≥0.36) 
positively associated with: each of the DIDP dimensions for participants with T1DM; 
‘emotional wellbeing’ and ‘dietary freedom’ dimensions for participants with T2DM 
(regardless of treatment); and ‘physical health’ among those with insulin-treated 
T2DM. Moderate correlations (rs ≥0.32) between general emotional wellbeing (PHQ-
8, GAD-7) and the ‘emotional wellbeing’ dimension were observed across groups, 
and with ‘physical health’ and ‘work/studies’ dimensions among participants with 
T1DM.   
Divergent validity of the 6-item and 7-item DIDP scales was confirmed across 
diabetes type/treatment groups.  
---Table 3---  
Table 4 details non-parametric known-group comparisons for the DIDP dimensions 
and 6-item and 7-item scale scores. Where signification differences were observed, 
effect sizes were small (r≤0.3).  
With the exception of dietary freedom, all scores differed significantly by diabetes 
type/treatment group. Pairwise comparisons revealed that participants with T1DM 
reported significantly more negative DIDP scores compared to those with T2DM 
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(both insulin and non-insulin treated), and participants with insulin-treated T2DM 
reported significantly more negative DIDP scores than those not using insulin.   
Among those with T1DM, no significant differences in DIDP scale scores were 
observed by insulin administration (injection versus pump), but differences were 
observed on two dimensions (‘finances’ and ‘dietary freedom’). Significant 
differences in all DIDP scale scores were observed by presence/absence of 
diabetes-related complications (all groups) and by experience of severe 
hypoglycaemia (T1DM only). 
---Table 4---  
4. Discussion 
The DIDP meets the need for a brief, contemporary measure assessing the impact 
of diabetes on key dimensions of life. High acceptability, strong internal consistency, 
and a robust single-scale structure are evidenced, separately by diabetes type and 
treatment, for the original, and modified 7-item, scale.  
Divergent validity was demonstrated across diabetes type/treatment groups for the 
6-item and 7-item scales. Importantly, DIDP scales scores were weakly associated 
with HbA1c and diabetes duration, demonstrating that the impact of diabetes on life 
cannot, and should not [31], be presumed from clinical characteristics alone. For the 
6-item and 7-item scales, convergent validity was confirmed in the T1DM sample, 
but not as strongly in the T2DM sample (regardless of treatment type). However, the 
‘emotional wellbeing’ dimension was at least moderately associated with diabetes-
specific distress and general emotional wellbeing across all groups. Further research 
is needed to investigate convergent validity in T2DM samples. 
  
 14 
Known-groups validity was established for the 6-item and 7-item DIDP and results 
were largely consistent with DAWN2 findings [14] and with long-form measures of 
diabetes-specific quality life [e.g. 5, 6, 22, 32, 33]. These results suggest that the 
DIDP may be able to discriminate at a population level between diabetes types, 
absence/presence of complications and severe hypoglycaemia (T1DM only), and 
major treatment types (e.g. tablets vs injections), but lacks sensitivity to more subtle 
differences (e.g. insulin administration modality: injection vs infusion). The DIDP 
assesses the broad impact of diabetes on various dimensions of life, which can 
include the impact of treatment but was not designed to focus on treatment-specific 
issues, e.g. convenience, efficacy, or side effects. When evaluating new treatments 
and technologies, it is important to use relevant measures of treatment 
satisfaction/burden [e.g. 34, 35].  
Given the brevity of the DIDP, we must consider whether the most appropriate 
dimensions of life are included and to what extent comprehensiveness is sacrificed 
for brevity. The DIDP dimensions cover several of the most discriminatory items of 
the ADDQoL [5, 22], one of the most widely used measures of diabetes-specific 
quality of life [36]. However, one potential omission of the 6-item DIDP is dietary 
freedom, which has been found to be the most negatively impaired aspect of life in 
several studies using the ADDQoL across diabetes types/treatments [20-22]. When 
dietary freedom was added to the DIDP, acceptability and reliability remained 
satisfactory, but the amount of variance explained by the scale dropped slightly. The 
seventh item performed as expected in terms of convergent and divergent validity 
but added little discriminatory power to known-groups analyses, except in relation to 
the difference between insulin administration modality (T1DM sample only). 
However, participants (especially those with T2DM) reported the most negative 
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impact of diabetes on the dietary freedom dimension. It may be that dietary freedom 
is more indicative of treatment satisfaction than quality of life per se. Indeed, the 
impact of insulin use on dietary freedom (what and when you eat) are included in the 
validated Insulin Treatment Satisfaction Questionnaire [34]. Regardless, further 
investigation of the relevance and importance of each of the DIDP’s dimensions, and 
consideration of other dimensions not currently captured (e.g. driving, 
independence), is warranted. For those considering use of the DIDP, inclusion of the 
dietary freedom item will depend upon the investigators’ study population and 
research question. For example, it would likely be useful in the evaluation of trials 
promoting flexible, intensive insulin therapy or a restricted low-carbohydrate dietary 
regimens [20]. 
The DIDP was deliberately worded neutrally with a bi-directional response scale to 
capture both positive and negative impacts of diabetes. It has been suggested that 
solely negatively-worded questionnaires may be upsetting or frustrating to 
respondents and susceptible to social desirability bias [37, 38]. Further, some people 
with diabetes perceive positive consequences of having diabetes (e.g. healthier 
lifestyles, friendships) [5, 39]. In the current study, positive impact of diabetes was 
reported by 5-17% of participants across life dimensions and groups, and all 
response options were used, confirming the previously described utility and 
acceptability of bi-directional response scales to assess the impact of diabetes [5].  
A strength of this study is the large sample, which enabled analyses to be conducted 
by diabetes type and treatment. DAWN2 results, including DIDP score distributions, 
internal consistency, and correlations with key clinical, demographic and 
psychosocial variable, have been reported elsewhere [13, 14]. However, 
psychometric properties were not reported in detail or examined separately by 
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diabetes type/treatment. Thus, the current study provides important psychometric 
evidence in support of the future use of the English version of the original 6-item and 
modified 7-item DIDP separately for adults with T1DM and T2DM. Future research 
should investigate cultural and linguistic equivalence, and psychometric properties of 
other DIDP language versions, as well as the caregiver versions [12, 13, 19, 40].   
Limitations of MILES-2 have been reported elsewhere [15]. Limitations described 
here are those specific to the current study. The MILES-2 study was designed to 
assess a wide range of constructs, enabling the examination of the hypothesised 
relationships between the DIDP and other clinical and psychosocial constructs for 
assessment of scale validity. However, clinical characteristics were self-reported and 
the study sample is relatively homogeneous [15]. Further, our ability to assess other 
forms of scale validity was limited due to the cross-sectional and non-interventional 
nature of the study as well as the exclusion of established long-form measures of 
diabetes-specific quality of life [4-6]. Future research should investigate the test-
retest reliability (reproducibility), concurrent and predictive validity of the DIDP as 
well as its sensitivity to change. Finally, MILES-2 participants were more likely to be 
English-speaking, highly educated, and employed compared to the Australian 
general population [15]. Future research examining the psychometric properties and 
acceptability of the DIDP (all language versions) should include hard-to-reach 
groups. 
In conclusion, the current study adds to the evidence for the DIDP, showing the 6-
item and 7-item scales are acceptable, valid and reliable brief measures of the 
perceived impact of diabetes in both T1DM and T2DM. The DIDP enables clinicians 
and researchers to take a holistic approach, reflecting on the values and preferences 
of people with diabetes, considering the perceived impact of their condition on 
  
 17 
various life dimensions. Further studies are needed to establish its utility in 
assessing the effect of clinical interventions, quality improvement programmes and 
policy, as well as the clinical utility of the DIDP in the delivery of individualised 
diabetes care.  
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Enquiries 
The DAWN2 Impact of Diabetes Profile is freely available for use. A copy of the 7-
item DIDP (English) for completion by adults with diabetes is shown in Supplement 
2. For further information about publicly available DIDP language versions, please 
email: sskovlund@dcm.aau.dk. 
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Table 1. Demographic, clinical and psychosocial characteristics (N=2,207) 
 T1DM T2DM: insulin T2DM: non-insulin 
Demographic 
characteristics 
n n(%) or 
mean±SD 
n n(%) or 
mean±SD 
n n(%) or 
mean±SD 
     Gender: Women 1012 598 (5.1) 504 197 (39.1) 691 312 (45.2) 
     Age, years 1012 44.2±15.2 504 61.3±8.9 691 61.2±9.5 
     Relationship status: In a 
relationship 
1008 
711 (70.5) 
504 
357 (70.8) 
688 
512 (74.4) 
     Employment status: In 
paid employment  
1012 
715 (70.7) 
504 
173 (34.3) 
691 
271 (39.2) 
     Education 1009  504  689  
              Less than year 12  127 (12.6)  156 (30.9)  153 (22.2) 
Completed high school  168 (16.7)  55 (10.9)  80 (11.6) 
Vocational education / 
diploma 
 
237 (23.5) 
 
160 (31.7) 
 
203 (29.5) 
University – undergraduate  251 (24.9)  73 (14.5)  139 (20.2) 
University – postgraduate  226 (22.4)  60 (11.9)  114 (16.5) 
     Country of birth: Australia 1012 780 (77.1) 504 368 (73) 691 470 (68.0) 
     Main language: English 1011 991 (98.0) 503 486 (96.6) 691 665 (96.2) 
Clinical characteristics n n(%) or 
mean±SD 
n n(%) or 
mean±SD 
n n(%) or 
mean±SD 
     Diabetes duration, years 1012 19.2±14.4 502 14.5±7.5 687 8.7±6.3 
     Primary treatment 1012  504  691  
Insulin pump  357 (35.3)  2 (0.4)  - 
Insulin injections  655 (64.7)  502 (99.6)  - 
Exenatide injections  -  -  40 (5.8) 
Blood glucose lowering 
tablets 
 
- 
 
- 
 
488 (70.6) 
Lifestyle modifications  -  -  163 (23.6) 
      Diabetes-related 
complications 
                      N                  
    ≥1 
complication 
999 
 
0.6±1.1 
344 (34) 
503 
 
1.4±1.5 
341 (68) 
687 
 
0.8±1.2 
299 (44) 
      HbA1c in past 6 months 
                                          % 
Mmol/mol 
795  
7.4±1.3 
57±14 
349  
7.5±1.6 
59±17 
404  
6.8±1.7 
51±18 
Severe hypoglycaemia in 
past 6 months
a
 
None  
≥1 
912 
 
760 (83.3) 
145 (16.7) 
351 
 
322 (91.7) 
29 (8.3) 
215 
 
205 (95.3) 
10 (4.7) 
Psychosocial 
characteristics 
N mean±SD 
median 
(IQR) 
n mean±SD 
median (IQR) 
n mean±SD 
median (IQR) 
     Diabetes-specific 
distress: PAID
b
 
882 25.1±21.1 
18.8 (7.5, 
38.8) 
446 23.0±20.7 
17.5 (6.3, 
34.0) 
588 
15.9±17.7 
10 (2.8, 21.2) 
     Depressive symptoms: 
PHQ-8 
1009 6.0±5.4 
5.0 (2.0, 
9.0) 
502 
7.7±6.1 
6.5 (2.0, 12.0) 
687 
5.6±5.1 
4.0 (1.0, 9.0) 
     Anxiety Symptoms:  
 GAD-7 
1010 4.7±4.9 
3.0 (1.0, 
7.0) 
502 
5.3±5.4 
4.0 (1.0, 8.0) 
690 
4.0±4.5 
2.0 (0.0, 6.0) 
     Prospective and 
retrospective 
memory: PRMQ 
991 35.5±10.7 
34.0 (28.0, 
42.0) 
493 36.5±10.9 
35.0 (29.0, 
43.0) 
666 35.0±9.9 
34.0 (28.0, 
41.0) 
     DIDP Physical health
c
 
1012 4.8±1.4 
5 (4,6) 
504 4.8±1.4 
5 (4,6) 
690 4.4±1.4 
5 (4,5) 
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     DIDP Financial situation
c
 
1012 5.0±1.1 
5 (4,6)  
504 4.6±1.3 
4 (4,5) 
691 4.5±1.1 
4 (4,6) 
     DIDP Relationships
c
 
1012 4.2±1.0 
4 (4,5) 
504 4.2±1.1 
4 (4,5) 
691 4.1±1.0 
4 (4,4) 
     DIDP Leisure activities
c
 
1011 4.7±1.2 
5 (4,5) 
504 4.6±1.3 
4 (4,5) 
691 4.2±1.3 
4 (4,5) 
     DIDP Work or studies
c
 
1012 4.7±1.1 
5 (4,5) 
502 4.4±1.1 
4 (4,5) 
690 4.3±1.0 
4 (4,4) 
     DIDP Emotional 
wellbeing
c
 
1011 5.0±1.2 
5 (4,6) 
503 4.7±1.3 
5 (4,6) 
690 4.6±1.2 
4 (4,5) 
     DIDP Dietary freedom
c
 
1012 5.1±1.4 
5 (4,6) 
503 5.0±1.6 
5 (4,6) 
691 5.0±1.4 
5 (4,6) 
     DIDP 6-item scale  
Composite score 
1001 4.7±0.94.7 
(4.3,5.3) 
500 4.6±1.0 
4.5 (4.0,5.2) 
673 4.4±0.9 
4.3 (4.0,4.7) 
Percentage score 
 62.3±15.0  
61.1 (55.6, 
72.2) 
 59.3±16.5 
58.3 (50.0, 
69.4) 
 55.8±15.6 
55.5 (50.0, 
61.1) 
     DIDP 7-item scale 
Composite score 
1007 4.8±0.9 
4.9 
(4.3,5.3) 
502 
4.6±1.0 
4.6 (4.0,5.3) 
678 
4.4±0.9 
4.4 (4.0,4.9) 
Percentage score 
 63.3±14.9 
64.3 
(55.5,71.4) 
 60.3±16.8 
59.5 (52.4, 
71.4)  
 57.3±15.4 
57.1 (50.0 
,64.3) 
a 
Question only asked of persons who previously reported having “ever” experience hypoglycaemia. 
b
 PAID data were not available for a subsample of participants (n=247; 11%), who 
were part of a longitudinal Diabetes MILES cohort and completed an alternate 
measure of distress consistent with the one they completed in 2011 [15].  
C
 For DIDP global dimensions, n includes those who reported the item was “not applicable”. These 
responses were not included in the calculation of summary statistics. 
DIDP: DAWN2 Impact of Diabetes Profile, PAID: Problem Areas in Diabetes, GAD-7: Generalized 
Anxiety Disorder questionnaire, PHQ-8: Patient Health Questionnaire, PRMQ: Prospective and 
Retrospective Memory Questionnaire, T1DM: Type 1 diabetes mellitus, T2DM: Type 2 diabetes 
mellitus 
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Table 2. Scale structure and internal consistency reliability for the 6-item and 7-item 
DIDP scales by diabetes type/treatment 
 6-item DIDP scale 7-item DIDP scale 
T1DM T2DM: 
insulin 
T2DM:  
non-insulin 
T1DM T2DM: 
insulin 
T2DM:    non-
insulin 
Factor 
loadings
a
 
      
Physical 
health 
.67 .70 .65 .67 .72 .67 
Financial 
situation 
.53 .67 .69 .54 .67 .70 
Relationships .66 .57 .83 .65 .56 .82 
Leisure 
activities 
.80 .83 .80 .79 .81 .79 
Work or 
studies 
.78 .77 .85 .78 .73 .84 
Emotional 
wellbeing 
.81 .82 .84 .82 .85 .87 
Dietary 
freedom 
- - - .58 .63 .50 
Eigenvalue 3.5 3.5 4.0 3.9 4.1 4.3 
Variance 
explained, % 
58.6 60.8 67.4 55.4 58.0 61.8 
Reliability        
Cronbach’s 
alpha 
0.85 0.87 0.90 0.86 0.87 0.88 
Guttman’s 
Lambda 
0.86 0.88 0.91 0.85 0.87 0.86 
a Factor loadings for unforced one-factor solution using principal axis factor analysis 
T1DM: Type 1 diabetes mellitus, T2DM: Type 2 diabetes mellitus 
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Table 3. Convergent and divergent validity of the DIDP dimensions and 6-item and 7-
item scale composite scores, by diabetes subgroup 
DIDP 
dimension / 
scale score 
Diabetes type / 
treatment 
PAID PHQ-8 GAD-7 PRMQ 
Diabetes 
duration 
Hba1c 
Physical 
health 
T1DM .45* .39* .32* .21* .01
ns
 .17* 
T2DM: insulin .34* .25* .18 .14 .03
 ns
 .17 
T2DM: NI .25 .25 .16 .17 .18 .17 
Financial 
situation 
T1DM .32* .27* .23* .15* .01
 ns
 .05
 ns
 
T2DM: insulin .18* .16* .11 .12* -.04
 ns
 .14 
T2DM: NI .18* .17* .11* .15* -.02
 ns
 .10 
Relationships 
T1DM .37* .29* .26* .16* .01
 ns
 .06* 
T2DM: insulin .15 .12 .16* .11 -.08
 ns
 .06
 ns
 
T2DM: NI .17* .14* .13 .14* -.01
 ns
 -.00
 ns
 
Leisure 
activities 
T1DM .44* .29* .27* .17* -.05
 ns
 .07
 ns
 
T2DM: insulin .27* .18* .15 .17* -.00
 ns
 .12 
T2DM: NI .19* .25* .16* .18* .13 .13 
Work or 
studies 
T1DM .46* .40* .35* .24* -.08 .09 
T2DM: insulin .21* .20* .19* .21* -.09 .11 
T2DM: NI .17* .16* .15* .17* -.04
 ns
 .02
 ns
 
Emotional 
wellbeing 
T1DM .66* .52* .50* .28* -.11* .13* 
T2DM: insulin .45* .37* .35* .25* -.09 .21* 
T2DM: NI .44* .34* .32* .24* .03
 ns
 .13* 
Dietary 
freedom 
T1DM .40* .23* .22* .18* -.15* .05
 ns
 
T2DM: insulin .36* .17* .19* .12 -.02
 ns
 .10
 ns
 
T2DM: NI .44* .25* .23* .17* .00
 ns
 .19* 
6-item scale 
T1DM .62* .49* .44* .27* -.05
 ns
 .14* 
T2DM: insulin .38* .27* .24* .20* -.04
 ns
 .21* 
T2DM: NI .35* .32* .24* .24* .12 .15 
7-item scale 
T1DM .62* .47* .43* .27* -.07 .13* 
T2DM: insulin .40* .27* .25* .19* -.03
 ns
 .20* 
T2DM: NI .38* .33* .25* .24* .11 .18* 
Data are Spearman’s rho correlations. Correlations consistent with hypothesised convergent 
and divergent validity of the DIDP scale scores are shown in bold text. 
All correlations are significant at a p-value <.05, unless otherwise noted: ns=not significant 
(p>.05); *=p<.001 
GAD-7: Generalized Anxiety Disorder questionnaire, NI: non-insulin, PAID: Problem Areas in 
Diabetes, PHQ-8: Patient Health Questionnaire, PRMQ: Prospective and Retrospective 
Memory Questionnaire, T1DM: Type 1 diabetes mellitus, T2DM: Type 2 diabetes mellitus
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Table 4. Known-groups comparison for the DIDP dimension and composite scores 
DIDP 
dimension / 
scale score 
Diabetes Type / Treatmenta 
Insulin 
administration:  
Inject vs Pumpb  
Diabetes-related 
complications:  
≥1 vs none 
Severe hypoglycaemia 
in past 6 months:  
≥1 vs none c 
T1DM vs  
T2DM: 
Insulin 
T1DM vs  
T2DM: NI 
T2DM:  
Insulin vs 
NI 
T1DM T1DM 
T2DM: 
Insulin 
T2DM: NI T1DM 
T2DM: 
Insulin 
Physical health -.01 ns .15* .16* .01 ns .16* .18* .14* .10 -.01 ns 
Financial 
situation 
.17* .26* .08 -.15* .14* .07 ns .02 ns .08 .00 ns 
Relationships .03 ns .08 .05 ns .01 ns .13* .07 ns .02 ns .10 .15 
Leisure 
activities 
.08 .24* .16* -.04 ns .10 .17* .20* .10 .05 ns 
Work or studies .16* .25* .09 .01 ns .11 .14 .07 ns .11 .15 
Emotional 
wellbeing 
.12* .22* .09 -.04 ns .09 .05 ns .04 ns .09 .02 ns 
Dietary freedom nc nc nc .14* .05 ns .09 ns .00 ns -.01 ns .00 ns 
6-item scale .12* .27* .15* -.06 ns .15* .14 .13  .12* .04 ns 
7-item scale .11* .24* .13* -.01 ns .15* .13 .12  .10 .04 ns 
Effect size (r) and p-levels reported are for pair-wise comparisons. Negative effect size indicates less negative impact reported by the reference 
group (first category/group listed) compared to the comparison group (second listed).   
All comparisons are significant at p-value <.05, unless otherwise noted: ns=not significant (p>.05); *=p<.001 
a statistics refer to pairwise comparisons conducting Kruskal-Wallis test comparing DIDP dimension and scale scores by diabetes type/treatment 
groups (T1DM, insulin-treated T2DM, non-insulin-treated T2DM). Pairwise comparisons only conducted where a significant difference by 
diabetes type/treatment was observed.  bInsulin administration comparison conducted for T1DM group only. c Comparison conducted for T1DM 
and T2DM insulin-treated only.  
nc = not calculated. NI= non-insulin using, T1DM: Type 1 diabetes mellitus, T2DM: Type 2 diabetes mellitus 
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Highlights 
 
 
 Diabetes-specific quality of life is widely acknowledged as an important 
clinical outcome.  
 However, existing measures are typically lengthy, complex, and negatively 
biased. 
 In response, the brief DAWN2 Impact of Diabetes Profile (DIDP) was 
developed. 
 The DIDP is an acceptable, valid and reliable measure of the impact of 
diabetes. 
 
 
